Clinical trials: Oral Cancers
Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer
Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
This project intends to make a study of personalized medicine evaluation system establishment for liver cancer, gastric cancer and nasopharynx cancer to provide strong support for the development of Precision Medicine and…
- Trial name
- NCT03260179
- Testing
- AL3810
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Select Relapsed/Refractory Lymphoid Malignancies
A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies.
- Trial name
- VIJAY-1 (NCT06761586)
- Testing
- AUR104
- Where
- 5 sites in India
- Volunteers
- 9 people
- Sponsor
- Aurigene Discovery Technologies Limited
Myeloid Leukemia, Philadelphia Positive
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
The aim of this study is to support development of asciminib in the pediatric population (1 to <18 years) previously treated with one or more TKIs.
- Trial name
- NCT04925479
- Testing
- Asciminib Pediatric formulation group, Asciminib Adult formulation group
- Where
- 39 sites in United States, China and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia
The purpose of this observational study is to assess the real-world safety of maintenance therapy with oral azacitidine in Korean participants with acute myeloid leukemia (AML) who achieved first complete remission (CR) or…
- Trial name
- NCT06073769
- Testing
- Oral azacitidine
- Where
- 2 sites in South Korea
- Volunteers
- 154 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for…
- Trial name
- VALOR (NCT05215639)
- Where
- 19 sites in Austria, Switzerland
- Volunteers
- 120 people
- Sponsor
- AbbVie
Advanced / Metastatic Solid Tumor
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint…
- Trial name
- NCT06063681
- Testing
- SR-8541A, Immune checkpoint inhibitor (ICI)
- Where
- 3 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Stingray Therapeutics
Prostatic Neoplasms
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once daily for approximately 4 weeks (+/- 2 weeks)…
- Trial name
- NCT00235794
- Testing
- temsirolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Malignant Melanoma, Neoplasms
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
This open-label, multi-center, three-period, one sequence study will investigate the effect of ketoconazole on the pharmacokinetics of vemurafenib in patients with unresectable BRAFV600-mutation positive metastatic melanoma or…
- Trial name
- NCT01765556
- Testing
- ketoconazole, vemurafenib
- Sponsor
- Hoffmann-La Roche
Advanced Oral and Maxillofacial Malignant Tumors
rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors
This is multicenter, open-label, randomized, active-controled, phase IV study of local direct intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , or combination with surgery for treatment of advanced oral…
- Trial name
- rAd-p53 (NCT00902083)
- Testing
- p53 gene with surgery, surgery, p53 with chemotherapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Refractory Leukemia, Acute Myelogenous Leukemia
Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
This study was to evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.
- Trial name
- NCT00880269
- Testing
- Panobinostat/LBH589
- Where
- 40 sites in United States, Australia and 10 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of E7050 when administered orally twice daily to patients with advanced…
- Trial name
- NCT00921869
- Testing
- E7050
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Eisai Co., Ltd.
Advanced Solid Tumors, Hematologic Malignancies
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate hepatic impairement or severe hepatic…
- Trial name
- NCT01912222
- Testing
- IXAZOMIB
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Relapsed/Refractory Multiple Myeloma
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with…
- Trial name
- NCT05308654
- Testing
- ABBV-453, Dexamethasone, Daratumumab
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- AbbVie
Carcinoma, Non-Small-Cell Lung
LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i.e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dose for the Phase II step.
- Trial name
- NCT00711594
- Testing
- BIBW 2992 MA2 40mg/day, BIBW 2992 MA2 50mg/day, BIBW 2992 MA2 20mg/day
- Where
- 20 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10
Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
Subjects will undergo baseline evaluation and an assessment of extent of disease. Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-10 based on a modified Fibonacci schema using a standard oncology 3+3…
- Trial name
- NCT03863145
- Testing
- CB-03-10
- Where
- 6 sites in United States
- Volunteers
- 90 people
- Sponsor
- Cosmo Technologies Ltd
Tumors, Prostate Cancer
A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel
This is a single-center, open-label (sequential-group dose-escalation dose-finding) phase I study of satraplatin and docetaxel in patients who have received prior chemotherapy regimens.
- Trial name
- NCT00313456
- Testing
- Satraplatin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Agennix
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable…
- Trial name
- NCT00504205
- Testing
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Hematologic Malignancy, Malignant Lymphoma
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
The purpose of this study is to evaluate the effect and safety of multiple doses of ketoconazole on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.
- Trial name
- NCT01324310
- Testing
- Romidepsin, Ketoconazole
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Celgene
Solid Tumor, Adult Lymphoma
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily.
- Trial name
- NCT05358379
- Testing
- CYC140
- Where
- 5 sites in United States, South Korea and 1 more
- Volunteers
- 330 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Cancer
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
The purpose of this study is to see how safe the study drug is and to determine the best dose to use in cancer patients in the future.
- Trial name
- NCT00920205
- Testing
- MPC-3100 (an Hsp90 inhibitor)
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Myrexis Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.